Verastem Oncology has confirmed the pricing of its latest public offering, raising around $90 million through a mix of common stock and pre-funded warrants. The biopharmaceutical firm, listed on Nasdaq under VSTM, specialises in therapies targeting RAS/MAPK pathway-driven cancers.
The company said the offering includes 8,543,794 shares of common stock priced at $7.25 each. Alongside this, it will issue pre-funded warrants covering up to 3,870,000 shares, priced at $7.2499 per warrant. That figure reflects the per-share offering price minus the $0.0001 exercise price attached to each warrant.
Gross proceeds are expected to total approximately $90 million before underwriting fees and other costs. Verastem has also granted underwriters a 30-day option to purchase an additional 1,862,069 shares at the same terms. Completion of the offering is anticipated on or around 17 November 2025, pending standard closing conditions. All securities in the offering are being issued directly by the company.
Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers, while H.C. Wainwright & Co. has been appointed as lead manager.
According to Verastem, the money raised will go towards commercial activities linked to AVMAPKI™ FAKZYNJA™ CO-PACK, which has approval from the U.S. Food and Drug Administration for treating KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer. Funds will also support ongoing clinical development of its product portfolio, including the VS-7375 oral KRAS G12D (ON/OFF) inhibitor programme, as well as general corporate and working capital needs.
